Nasdaq · CIK 0001094038
MRKR Marker Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Nov 19, 2025. Close $0.97 on Oct 9, 2026, +13% from the 52-week low and -56% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Price and insider trades, last year
MRKROct 9, 2026 · close 0.97
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Marker Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | Steve Elms director buy | $35k 11,085 shares | +4% | - | |
| 50Moderate | New Enterprise Associates 16, L.P. owner buy | $1.8M 554,250 shares | +52% | - |
Transactions
The last 12 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | Steve Elms director | AGrant or award Stock Option (right to buy)derivative | +84,411 | $0.00 | $0 | 84,411 | Nov 19, 2025 |
| Nov 17, 2025 | Norman David Eansor director | AGrant or award Stock Option (Right to Buy)derivative | +84,411 | $0.00 | $0 | 84,411 | Nov 19, 2025 |
| Nov 17, 2025 | Katharine Knobil director | AGrant or award Stock Option (Right to Buy)derivative | +84,411 | $0.00 | $0 | 84,411 | Nov 19, 2025 |
| Nov 17, 2025 | Steve Elms director | AGrant or award Stock Option (right to buy)derivative | +137,330 | $0.00 | $0 | 137,330 | Nov 19, 2025 |
| Nov 17, 2025 | Norman David Eansor director | AGrant or award Stock Option (Right to Buy)derivative | +137,330 | $0.00 | $0 | 137,330 | Nov 19, 2025 |
| Nov 17, 2025 | Katharine Knobil director | AGrant or award Stock Option (Right to Buy)derivative | +137,330 | $0.00 | $0 | 137,330 | Nov 19, 2025 |
| Oct 31, 2025 | Kathryn Penkus Corzo director | AGrant or award Stock Option (Right to Buy)derivative | +147,611 | $0.00 | $0 | 147,611 | Nov 4, 2025 |
| Feb 12, 2025 | Steve Elms director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 14, 2025 |
| Feb 12, 2025 | Norman David Eansor director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 14, 2025 |
| Feb 12, 2025 | Katharine Knobil director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Feb 14, 2025 |
| Dec 23, 2024 | Steve Elms director | POpen-market purchase Common Stockindirect: See Footnote | +11,085 | $3.20 | $35k | 325,370 | Dec 26, 2024 |
| Dec 23, 2024 | New Enterprise Associates 16, L.P. owner | POpen-market purchase Common Stock | +554,250 | $3.20 | $1.8M | 1,625,678 | Dec 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Kathryn Penkus Corzodirector
- Steve Elmsdirector
- Norman David Eansordirector
- Katharine Knobildirector
- New Enterprise Associates 16, L.P.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.